Impact of protease inhibitors and other antiretroviral treatments on acquired immunodeficiency syndrome survival in San Francisco, California, 1987-1996

被引:51
作者
Schwarcz, SK
Hsu, LC
Vittinghoff, E
Katz, MH
机构
[1] San Francisco Dept Publ Hlth, San Francisco, CA 94102 USA
[2] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
关键词
acquired immunodeficiency syndrome; HIV; HIV protease inhibitors; protease inhibitors; survival;
D O I
10.1093/aje/152.2.178
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The authors assessed temporal trends in acquired immunodeficiency syndrome (AIDS) survival for 15,271 persons in San Francisco, California, diagnosed between 1987 and 1996 with an opportunistic illness included in the 1987 AIDS case definition. Predictors of survival were evaluated for 5,686 persons who were diagnosed between 1993 and 1996 and met the 1993 AIDS case definition. Median survival was 19 months for persons diagnosed between 1987 and 1989, 17 months for persons diagnosed between 1990 and 1992, 15 months for persons diagnosed between 1993 and 1994, and 31 months for persons diagnosed between 1995 and 1996. Decreased mortality was associated with use of antiretroviral therapy without protease inhibitors before AIDS (relative hazard (RH) = 0.88, 95% confidence interval (CI): 0.8, 1.0) and after AIDS (RH = 0.83, 95% CI: 0.7, 0.9) and use of antiretroviral agents with protease inhibitors before AIDS (RH = 0.25, 95% CI: 0.2, 0.3) and after AIDS (RH = 0.36, 95% CI: 0.3, 0.4). Increased mortality was found for persons aged greater than or equal to 40 years (RH = 1.43, 95% CI: 1.3, 1.6), persons initially diagnosed with an opportunistic illness (RH = 1.97, 95% CI: 1.8, 2.2), and homosexual injection drug users (RH = 1.33, 95% CI: 1.2, 1.5). Survival after AIDS has increased. Treatment with antiretroviral agents, particularly protease inhibitors, strongly predicts improved survival.
引用
收藏
页码:178 / 185
页数:8
相关论文
共 69 条
[1]   A COMPARATIVE TRIAL OF DIDANOSINE OR ZALCITABINE AFTER TREATMENT WITH ZIDOVUDINE IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
ABRAMS, DI ;
GOLDMAN, AI ;
LAUNER, C ;
KORVICK, JA ;
NEATON, JD ;
CRANE, LR ;
GRODESKY, M ;
WAKEFIELD, S ;
MUTH, K ;
KORNEGAY, S ;
COHN, DL ;
HARRIS, A ;
LUSKINHAWK, R ;
MARKOWITZ, N ;
SAMPSON, JH ;
THOMPSON, M ;
DEYTON, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (10) :657-662
[2]  
[Anonymous], 1987, MMWR-MORBID MORTAL W
[3]   TRENDS IN MORTALITY AMONG AIDS PATIENTS IN AMSTERDAM, 1982-1988 [J].
BINDELS, PJ ;
POOS, RMJ ;
JONG, JT ;
MULDER, JW ;
JAGER, HJC ;
COUTINHO, RA .
AIDS, 1991, 5 (07) :853-858
[4]   TRENDS IN SURVIVAL AMONG PERSONS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME IN NEW-YORK-CITY - THE EXPERIENCE OF THE FIRST DECADE OF THE EPIDEMIC [J].
BLUM, S ;
SINGH, TP ;
GIBBONS, J ;
FORDYCE, EJ ;
LESSNER, L ;
CHIASSON, MA ;
WEISFUSE, IB ;
THOMAS, PA .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1994, 139 (04) :351-361
[5]  
BROERS B, 1994, ARCH INTERN MED, V154, P1121, DOI 10.1001/archinte.154.10.1121
[6]  
CDC (Cent. Dis. Control Prev.), 1992, MMWR RECOMM REP, V41, P1
[7]   Self-reported antiretroviral therapy in injection drug users [J].
Celentano, DD ;
Vlahov, D ;
Cohn, S ;
Shadle, VM ;
Obasanjo, O ;
Moore, RD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (06) :544-546
[8]   RACE, SEX, DRUG-USE, AND PROGRESSION OF HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE [J].
CHAISSON, RE ;
KERULY, JC ;
MOORE, RD .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (12) :751-756
[9]   SURVIVAL AND MORTALITY PATTERNS OF AN ACQUIRED-IMMUNODEFICIENCY-SYNDROME (AIDS) COHORT IN NEW-YORK-STATE [J].
CHANG, HGH ;
MORSE, DL ;
NOONAN, C ;
COLES, B ;
MIKL, J ;
ROSEN, A ;
PUTNAM, D ;
SMITH, PF .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1993, 138 (05) :341-349
[10]   THE NEW AIDS CASE DEFINITION - IMPLICATIONS FOR SAN-FRANCISCO [J].
CHANG, SW ;
KATZ, MH ;
HERNANDEZ, SR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (07) :973-975